Amryt Pharma is confident of repeating last year's successes in 2021, with preparations well underway for the possible launch of Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa (EB), a rare genetic condition where skin can tear at the slightest touch.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?